The company plans to submit a new drug application for tavapadon to the US Food and Drug Administration next year.

Researchers have suspected for some time that the link between our gut and brain plays a role in the development of Parkinson ...

Tavapadon aims to treat Parkinson’s motor symptoms by mimicking dopamine in a once-a-day oral dose. And the pivotal, ...

AbbVie Inc. announced positive data from a third late-stage trial of a treatment for Parkinson’s disease on Monday and said ...

This fall, the Montreal Neurological Institute and Hospital (The Neuro, at McGill University and the McGill University Health Centre) expects to introduce a previously unavailable form of treatment ...

Intra-Cellular Therapies is developing Lenrispodun for the treatment of patients with Parkinson's Disease in a phase 2 study.

If you notice more than one of these symptoms, it's worth discussing them with your doctor. Trouble Moving or Walking ...

Clinical studies have revealed that rasagiline is associated with improved outcomes in patients with early Parkinson's disease ... patients may be more prone to treatment-emergent adverse ...

People with Parkinson’s disease are to benefit from cutting edge AI technology that allows neuroscientists to safely test medication and treatment on a ‘digital twin’ brain, thanks to a £1m funding ...

“The positive results across all three Phase 3 TEMPO trials underscore the potential of tavapadon as a first-in-class D1/D5 ...

AbbVie's experimental drug to treat early Parkinson's disease helped significantly improve patients' ability to carry out ...